There aren't many opportunities for CSL to grow by acquisition, so the way to boost the share price is to keep buying back shares and increasing value for shareholders... If they have the money then why not? Personally I think opportunities in stem cell research is a good way to diversify away from plasma products and MSB as a takeover target, but that's my personal opinion... I don't think any shareholders would complain about the recent and past share price performance, it has been sensational and so have the management... I should also point out that I am employed by CSL and have been working there for the past 6 years...
should csl still be buying back shares?, page-4
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$305.34 |
Change
4.220(1.40%) |
Mkt cap ! $147.5B | |||
| Open | High | Low | Value | Volume |
| $303.92 | $305.98 | $302.00 | $378.0M | 1.257M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 74 | $305.22 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $305.43 | 250 | 1 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| CSL (ASX) Chart |